<DOC>
	<DOCNO>NCT01213849</DOCNO>
	<brief_summary>The purpose study demonstrate dose proportionality fluticasone furoate ( FF ) equivalence vilanterol ( VI ) follow single dose administration FF/VI via novel dry powder inhaler healthy subject .</brief_summary>
	<brief_title>Dose Proportionality Study : Blood Levels Fluticasone Furoate ( FF ) Vilanterol ( VI ) Following Different Doses FF/VI Via Inhaler</brief_title>
	<detailed_description>The study open-label , randomise , 3-way cross-over single dose study 24 healthy subject demonstrate dose proportionality fluticasone furoate ( FF ) equivalence vilanterol ( VI ) follow single dose administration FF/VI via novel dry powder inhaler . In 3 treatment period , subject receive 4 inhalation 50/25 mcg , 100/25 mcg , 200/25 mcg FF/VI . Blood sample take pharmacokinetic analysis safety ( 12-lead ECGs , clinical laboratory test , vital sign , adverse event ) monitor follow dose .</detailed_description>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin &lt; or= 1.5xULN Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . Male female 18 65 year age inclusive . A female subject eligible participate : Nonchildbearing potential define postmenopausal female document tubal ligation hysterectomy , postmenopausal define 12 month spontaneous amenorrhea . Childbearing potential agrees use one approve contraception method 16 week last dose . Male subject female partner childbearing potential must agree use one approve contraception method 16 week last dose . Body Mass Index ( BMI ) within range 18.529.0 kg/m2 ( inclusive ) . Capable give informed consent , include compliance requirement restriction list consent form . Average QTcF &lt; 450 msec . No clinically significant abnormality Holter electrocardiogram ( ECG ) screening . Subjects current nonsmoker , use tobacco product 12 month period precede screen visit , pack history &lt; = 5 pack year . Able satisfactorily use dry powder inhaler . As result medical interview , physical examination screen investigation , principal investigator delegate physician deems subject unsuitable study . Subjects must systolic blood pressure 145 mmHg diastolic pressure 85 mmHg unless Investigator confirm satisfactory age . The subject history breathing problem adult life ( e.g . history asthmatic symptomatology ) . Screening lung function test ( forced expiratory volume 1 minute ( FEV1 ) ) perform confirm normal lung function parameter ( &gt; or=85 % predict ) . Subjects suffer low respiratory tract infection within 4 week screen visit . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . The subject treat diagnosed depression within six month screen history significant psychiatric illness . A positive HIV antibody . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . History heavy regular alcohol consumption within 6 month study define : average weekly intake &gt; 21 unit male &gt; 14 unit female . History regular use tobacco nicotinecontaining product within 12 month prior screen . Positive carbon monoxide alcohol breath test screen admission unit . A positive prestudy urine drug screen randomly test study . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 3 month , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . The subject take systemic , oral depot corticosteroid less 12 week screen visit . The subject take inhaled , intranasal topical steroid le 4 week screen visit . History sensitivity adverse reaction study medication include immediate delay hypersensitivity betaagonist , sympathomimetic drug , intranasal , inhaled systemic corticosteroid ; know suspected sensitivity constituent new powder inhaler ( lactose magnesium stearate ) history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . History severe milk protein allergy . Where participation study would result donation blood blood product excess 500 mL within 3 month start study . Pregnant female determine positive serum hCG test screen positive serum/urine hCG test prior dose . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . Consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>